CanB, a Druggable Cellular Target in Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Drug-resistant tuberculosis poses a significant global health threat, necessitating the development of novel therapeutic strategies.
• Identifying new drug targets in Mycobacterium tuberculosis is essential for creating effective treatments against resistant strains.

Purpose of the Study:

• To establish a workflow for validating new drug targets and inhibitors against Mycobacterium tuberculosis.
• To investigate the essentiality of the β-carbonic anhydrase CanB in M. tuberculosis survival and to identify CanB inhibitors.

Main Methods:

• Construction of conditional M. tuberculosis canB mutants using the Pip-ON system.
• In silico molecular docking to identify potential CanB inhibitors.
• In vitro antimicrobial assays (MIC, time-killing) and enzymological studies (enzymatic assays, differential scanning fluorimetry).

Main Results:

• CanB was confirmed as essential for M. tuberculosis survival in vitro.
• Three novel compounds were identified that inhibit M. tuberculosis growth and exhibit high affinity for CanB.
• The lead compound demonstrated bactericidal activity.

Conclusions:

• The validated workflow effectively integrates genetic, in silico, and enzymological methods for target and inhibitor discovery.
• CanB is a promising drug target for developing new anti-tubercular agents.
• The identified compounds represent potential leads for novel tuberculosis therapeutics.